Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An open source business model for malaria.

Christine Årdal1, John-Arne Røttingen2

  • 1Department of International Public Health, Norwegian Institute of Public Health, Oslo, Norway; Section for Global Health, Norwegian Knowledge Centre for the Health Services, Oslo, Norway.

Plos One
|February 7, 2015
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tackling the global health research financing emergency to sustain national health research ecosystems.

Lancet (London, England)·2026
Same author

Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach.

The Lancet regional health. Europe·2026
Same author

Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance.

Nature communications·2025
Same author

Closing the deal: a G20 panel report on financing for pandemic threats.

Lancet (London, England)·2025
Same author

Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements.

BMJ (Clinical research ed.)·2025
Same author

Functions of the global health system in a new era.

Nature medicine·2025

Greater investment in malaria R&D is needed. An open-source approach, with increased transparency and data sharing, can enhance malaria drug and vaccine development, leading to greater collaboration and impact.

Area of Science:

  • Malariology
  • Drug Discovery and Development
  • Intellectual Property in Public Health

Background:

  • Significant investment is required for malaria eradication through new drugs and vaccines.
  • Existing malaria research and development (R&D) efforts need careful management for maximum impact.

Purpose of the Study:

  • To evaluate current malaria R&D for new drugs and vaccines.
  • To determine how an enhanced open-source approach can benefit malaria R&D.
  • To assess the operational aspects of an open-source business model for malaria R&D.

Main Methods:

  • Assessment of research articles, patents, and clinical trials.
  • Conducting a survey among malaria researchers.
  • Analysis of the public and philanthropic funding landscape for malaria R&D.

Related Experiment Videos

Main Results:

  • Public and philanthropic sectors fund most malaria drug/vaccine discovery and development.
  • Access to discoveries is restricted by patents, closed publications, and inaccessible specimens.
  • Malaria researchers expressed willingness to use shared registry data to increase collaboration.

Conclusions:

  • An open-source approach with greater transparency can improve efficiency and foster collaborations in malaria R&D.
  • Empowering organizations like the Medicines for Malaria Venture (MMV) as data clearing houses is recommended.
  • The utility of patents for publicly funded malaria medicines, with limited profit potential, warrants re-evaluation, considering alternative incentives like WHO prequalification.